Titlebook: Brain Tumor Immunotherapy; Linda M. Liau,Donald P. Becker,Darell D. Bigner Book 2001 Springer Science+Business Media New York 2001 apoptos

hearken

書目名稱Brain Tumor Immunotherapy影響因子(影響力)




書目名稱Brain Tumor Immunotherapy影響因子(影響力)學(xué)科排名




書目名稱Brain Tumor Immunotherapy網(wǎng)絡(luò)公開度




書目名稱Brain Tumor Immunotherapy網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Brain Tumor Immunotherapy被引頻次




書目名稱Brain Tumor Immunotherapy被引頻次學(xué)科排名




書目名稱Brain Tumor Immunotherapy年度引用




書目名稱Brain Tumor Immunotherapy年度引用學(xué)科排名




書目名稱Brain Tumor Immunotherapy讀者反饋




書目名稱Brain Tumor Immunotherapy讀者反饋學(xué)科排名

INERT

時(shí)代錯(cuò)誤

全等

Biological Principles of Brain Tumor Immunotherapyd the presence of CNS complement, are presented as well, because these areas represent new potential areas for therapeutic intervention. Discussion of application of this information, including manipulation of cytokines, adoptive IT, vaccination, and tumor-specific Ag approaches, is reserved for other chapters.

conifer

Book 2001unotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics.

信條

Book 2001therapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the fie

Ischemia

Hyperlipidemia

壁畫

Systemic T-Cell Immunotherapy for Brain Tumorsafferent immune response (IR) Indeed, early studies using transplantation of allogeneic tissues established the concept of “immune privilege” for the brain .. However, there is ample clinical ., and experimental . evidence that the brain is permissive for T-cell-mediated efferent IRs.

Flawless